



To NASDAQ OMX Copenhagen A/S
Announcement No. 13-10 / Copenhagen, 13 April, 2010

Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

Topotarget designates Professor Jean-Louis Misset as Chairman of its Global Medical and Scientific Advisory Board

Copenhagen, Denmark – 13 April 2010 – Topotarget A/S (NASDAQ OMX: TOPO) designates Professor Jean-Louis Misset as Chairman of its Medical and Scientific Advisory Board. Jean-Louis Misset is a full professor of oncology at the University and at the St. Louis Hospital Oncology Division in Paris, France. Professor Misset is an experienced Key Opinion Leader within oncology who has served as an advisor to several big Pharma Companies.

"I am very proud that Professor Jean-Louis Misset has accepted the position to Chair Topotarget's Global Medical and Scientific Advisory Board. As I stated earlier belinostat is a pipeline in a single molecule and has blockbuster potential. Professor Misset will provide Topotarget with expert leadership to help select the best clinical development path for belinostat and for the other products in the pipeline," said the CEO of Topotarget, Francois Martelet, MD. "With the guidance of this Advisory Board we will drive our medical strategy forward with the aim of full exploitation of belinostat's medical and commercial potential".

Professor Misset has a strong oncology background as an advisor in the field of drug development. As a member of scientific boards and as an advisor Professor Misset has experience of the clinical development of drugs including Topotecan (SmithKlineBeecham), Docetaxel (Aventis), Alimta (Eli Lilly) and Herceptin (Roche). Professor Misset will be building a board of highlevel senior drug development people and key opinion leaders in their fields.

"I am very pleased to accept the assignment as Chairman of the Scientific Advisory Board for belinostat. Belinostat has an interesting activity and safety profile with the ability to combine with many active anti-cancer agents both in hematological cancers and in solid tumors. The right strategy regarding choice of indications, treatment schedules and doses are critical for the success of belinostat, and I look forward to work with the Topotarget and Spectrum teams", said Professor Jean-Louis Misset.

Today's news does not change Topotarget's full-year financial guidance.



Topotarget designates Professor Jean-Louis Misset
as Chairman of its Global Medical and Scientific
Advisory Board

Topotarget A/S

For further information, please contact:

Francois Martelet	Direct	+45 39 17 94 99
CEO	Mobil	+45 31 36 83 41

Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. Topotarget currently focuses, in collaboration with Spectrum Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug candidate, Belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within PTCL (peripheral T-cell lymphoma). Topotarget is directing its efforts on belinostat and on additional key cancer targets, including HDACi, NAD+, mTOR, FASLigand and topoisomerase II inhibitors. The Company's first marketed product, Savene®/Totect®, was approved by EMEA in 2006 and the FDA in 2007, and is marketed by Topotarget's own sales force in the US. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Topotarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of Topotarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; Topotarget's history of incurring losses and the uncertainty of achieving profitability; Topotarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against Topotarget's products, processes and technologies; the ability to protect Topotarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.